IVI in the Media
13th Vaccinology Course Hosted by IVI Concludes Successfully
13th International Advanced Course on Vaccinology, IVI’s Program to Increase Developing Country's Capacity in Vaccine Research and Immunization, Concludes Successfully
May 20, 2013, Seoul, South Korea— The International Vaccine Institute (IVI), the first international organization headquartered in South Korea, successfully concluded the 13th International Advanced Course on Vaccinology in the Asia-Pacific Region. The popular week-long course, the first vaccinology course of its kind in the Asia-Pacific region, aims to build capacity of health professionals and decision-makers, especially those from developing countries, in all areas of the vaccine spectrum: vaccine development, evaluation, production and policy.
This year, over 67 participants from 22 countries including, the Bangladesh, China, India, Nigeria, Sudan, Thailand and Vietnam participated in the course. The participants were a diverse mix of scientists, public health officials, and policymakers from private and public sectors including 14 fellowships.
“This year’s course focused on the vaccine development process, and the method for vaccine evaluation,” said Dr. Soon-Ae Kim, research scientist at IVI who worked as Course Coordinator. “The course also provided information on a range of vaccine-preventable diseases including Hepatitis E, Human Papilloma Virus, Tuberculosis, HIV, influenza and Malaria.”
Lectures by leading experts in vaccinology, roundtable discussions, and interactive case studies were conducted on a wide range of disciplines, including epidemiology and immunology, the latest in vaccine technology, regulatory issues, and vaccine economics and financing. More than 30 experts from IVI, universities, research institutions, industry, non-profit organizations, and international agencies served as faculty members.
Dr. Gregory Dudley Hussey from the University of Cape Town, gave a keynote closing speech on May 18 entitled ‘Vaccine research and development: past, present and future.’ Dr. Francois Meurice, Vice president of Global Medical Affairs Scientific affairs and Medical Education at GlaxoSmithKline, also spoke on the method for vaccine evaluation through Phase I, II, and III clinical trial and post-licensure.
“IVI believes that capacity building is essential in ensuring that safe, effective, and affordable vaccines are discovered, developed and delivered to developing nations,” said Dr. Christian Loucq, IVI Director General. “We are thrilled to conclude yet another successful course on vaccinology, and we look forward to continuing to provide high quality training for healthcare professionals to ensure vaccines are utilized in mitigating infectious disease risk.”
The course was supported by GlaxoSmithKline Biologicals, Pfizer Corporation Hong Kong Limited the Korea Exchange Bank Foundation, the Export Import Bank of Korea, as well as the Korean Ministry of Education.
The International Vaccine Institute (IVI) is the world’s only international organization devoted exclusively to developing and introducing new and improved vaccines to protect the world’s poorest people, especially children in developing countries. Established in 1997, IVI operates as an independent international organization under a treaty signed by 35 countries and the World Health Organization. The Institute conducts research in more than 30 countries of Asia, Africa and Latin America on vaccines against diarrheal infections, bacterial meningitis and pneumonia, as well as Japanese encephalitis and dengue fever, and develops new and improved vaccines at its headquarters in Seoul, Republic of Korea. For more information, please visit www.ivi.int.
Tae Kyung Byun
Public Awareness/Advocacy Officer, IVI
Phone: +82-2-872-2801 (Ext. 159)